baber/WOPTO huggingface dataset:
Patent NZ-244782-A (NZ)
Title: Isolated peptides having t-cell stimulating activity, pharmaceutical composition
Inventor: GARMAN RICHARD D
IPC: A61K39/35
Filed: 1992-10-16
Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.
Patent NZ-254013-A (NZ)
Title: Nucleic acid molecule encoding plant flavonoid glycosylating enzyme and its use in manipulating production of pigment molecules in plants
Inventor: BRUGLIERA FILIPPA
IPC: C12N15/09
Filed: 1993-07-30
Abstract: PCT No. PCT/AU93/00387 Sec. 371 Date Mar. 13, 1995 Sec. 102(e) Date Mar. 13, 1995 PCT Filed Jul. 30, 1993 PCT Pub. No. WO94/03591 PCT Pub. Date Feb. 17, 1994The present invention relates generally to genetic sequences encoding flavonoid pathway metabolising enzymes and in particular flavonoid glycosylating enzymes and their use such as in manipulating production of pigmentory molecules in plants. More particularly the present invention provides a genetic sequence encoding UDP rhamnose: anthocyanidin-3-glucoside rhamnosyltransferase (3RT).
Patent NZ-326859-A (NZ)
Title: Remote programming of mobile with codec algorithms in accordance with call quality requirements
Inventor: GOETZ IAN
IPC: H04W92/10
Filed: 1997-01-30
Abstract: During the registration process by which a connection is set up between a mobile phone and a base station , the telephone acquires program data from the network for controlling its operation.  This allows upgrades of the system to be provided automatically to the mobile telephone.  During the registration process the base station 10 transmits a signal indicative of a preferred mode of operation.  The mobile telephone 1 responds with a signal that indicates whether it already has the program data in its memory.  If the phone indicates that it does not have the program data, the required data is transmitted to the mobile phone.  The base station and mobile telephone then operate in the preferred mode.  A check is made to see if the mobile telephone is capable of accepting the data.  If it cannot, for example because of insufficient memory, the process is repeated with different programs until one is found for which there is sufficient capacity.  If a call attempt is made before this process is complete, the process is curtailed.
Patent NZ-329770-A (NZ)
Title: Ruminal bolus for electronic identification of a ruminant
Inventor: LOPEZ GERADO CAJA
IPC: A01K11/00
Filed: 1997-04-25
Abstract: his bolus for electronically identifying a ruminant is designed to be received in the reticulum of the ruminant and comprises a body itself having a housing designed to contain a data interchange device. The bolus is characterized in that the body is made of a material based on alumina (Al2O3).
Patent NZ-332478-A (NZ)
Title: Use of collagenase-3 selective inhibitors for treating joint diseases
Inventor: MCCLURE KIM FRANCIS
IPC: A61K31/34
Filed: 1998-10-23
Abstract: The use of a collagenase-3 selective inhibitor or a pharmaceutically acceptable salt thereof, for the preparation of medicaments for treating or preventing disorders characterised by cartilage damage or loss of joint function such as osteoarthritis, rheumatoid arthritis and cancer. The collagenase-3 selective inhibitors are selected from: a) 1-{[4-(4-flurophenoxy)benzenesulfonyl]-pyridin-3-ylmethyl-amino}-cyclopentanecarboxylic acid; b) 2-{[4-(4-flurophenoxy)benzenesulfonyl]-pyridin-3-ylmethyl-amino}_N-hydroxy-2-methyl-propionamide; c) (4-benzyl-benzyl)-[2-(2,2-dimethyl-1-methylcarbamoyl-propylcarbamoyl)-6-phenoxyhexyl]-phosphinic acid, d) 2-amino-3-[4-(4-fluorophenoxy)benzenesulfonyl]-N-hydroxy-propionamide, e) N-hydroxy-2-[(4-phenoxy-benzenesulfonyl)-pyridin-3-ylmethyl-amino]-acetamide, f) (4-benzyl-benzyl)-{2-[2-(4-methoxy-penyl)-1-methylcarbamoyl-ethylcarbamoyl]-6-pheoxy-hexyl}-phosphinic acid, g) 3-[4-(4-fluorophenoxy)benzenesulfonyl]-2,N-dihydroxy-propionamide; h) 2-{1-[4-(4-fluorophenoxy)benzenesulfonyl]-cyclobutyl}-2,N-dihydroxy-acetamide; i) 3-(4-phenoxybenzenesulfonyl)-7-oxa-bicyclo(2.2.1]heptane-2-carboxylic hydroxyamide; j) 2-[4-(4-fluorophenoxy)benzenesulfonyl-amino]-N-hydroxy-2-methyl-propionamide; k) 1-[4-(4-fluorophenoxy)benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid; l) 4-(4'-chlorobiphenyl-4-yl)-2-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)ethyl]-4-oxobutyric acid; m)4-{4-(4-chlorophenoxy)benzenesulfonylmethyl]-tetrahydropyran-4-carboxylic hydroxamide; n) (S)-a-[2-(4'-chloro(1,1'-biphenyl]-4-yl)-2-oxoethyl]-1,3-dihyro-1,3-dioxo-2H-isoindole-2-butanoic acid; o) 4-[4-(4-chlorophenoxy)phenylsulfonylmethyl]-tetrahydropyran-4-(N-hydrocarboxamide); and p) 3(S)-N-hydroxy-4-(4-((pyrid-4-yl)oxy)benzenesulfonyl)-2,2-dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide.
Patent NZ-333006-A (NZ)
Title: Non-transformant immortalized avian cell lines derived from avian fibroblasts and epithelial cells there are immortalised by the SV40 T+t gene in the dependence on the MTI promoter
Inventor: BOUQUET JEAN-FRANCOIS
IPC: C12N7/01
Filed: 1997-05-22
Abstract: A non-transformant immortal avian cell, in particular derived from avian tissue, i.e. other than blood or haemotopoietic cells, particularly fibroblasts and epithelial cells, for instance of embryos. The avian cells are immortalised by the SV40 T+t gene in the dependence of the MTI (murine metallothionein I) promoter. In particular they integrate the pDAMT vector. Preferably, the cells also integrate at least one LTR sequence which could be deleted.
Patent NZ-504119-A (NZ)
Title: Water dispersible polymeric compositions
Inventor: ANDERSON JEFFREY L
IPC: C09D11/02
Filed: 1998-11-12
Abstract: Described is an aqueous polymeric dispersion, comprising: (i)    a non-gelled polymeric composition comprising the reaction product of an A polymer which is an addition polymer having an average of 3.5 or more reactive functional groups per polymer chain and a B polymer having 2 to 3 functional groups per polymer chain that are co-reactive with the reactive functional groups of the A polymer, and (ii)    water, and (iii)   optionally a solubilizing agent. Wherein substantially all of the co-reactive functional groups of the B polymer have been co-reacted and a molar ratio of A polymer to B polymer is 3:1 to 2:1.7. Also described is an emulsion polymer, comprising a support resin emulsion polymerized with at least one ethylenically unsaturated monomer, the support resin being the aqueous polymeric dispersion described above.
Patent NZ-506251-A (NZ)
Title: Benzothiadiazine and benzothiadiazepine derivatives and their use as positive AMPA receptor modulators
Inventor: OLSEN GUNNAR M
IPC: C07D285/24
Filed: 1999-02-18
Abstract: The compound of the formula shown, where: X is SO2; Y is CH(R4), N(R4), N(R4)-CH2 or O; R2 is H R3 is H, cycloalkyl, alkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkoxy, haloalkoxy, -alkyl-NR13R14, -alkyl-S-R13, an optionally substituted carbocyclic 7- to 12- membered ring, an optionally substituted heterocyclic 3- to 8- membered ring (optionally fused to an aryl), optionally substituted benzyl; or R3 and R4 together with the atoms to which they are attached form an optionally substituted 4- to 7- membered ring that optionally contains heteroatoms and carbonyl groups. R4 is H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, -CO-R10, or CO2R10; R5 is H, halogen, alkyl, alkenyl, alkynyl, aryl, or -SO2-NR11R12; R6 is H, halogen, alkyl, cyano, cyanoalkyl, nitro, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, cyclohaloalkyl, -NR15R16, -NHSO2-R15, -NHSO2-aryl, optionally substituted aryl, optionally substituted heterocyclic, -(alkyl)m-S-R15, -(alkyl)m-SO-R15, -(alkyl)m-SO2-R15, -(alkyl)m-SO2OR15, -(alkyl)m-SO2-NR15R16, -(alkyl)m-NHCOR15, -(alkyl)m-CONR15R16, -(alkyl)m-CR'=NOR", -(alkyl)m-CO-R15, or -(alkyl)m-CO2-R15; R7 is halogen, alkyl, cyano, cyanoalkyl, nitroalkyl, alkoxy, haloalkoxy, haloalkyl, hydroalkyl, cycloalkyl, cyclohaloalkyl, -NR17R18, -NHSO2-R17, -NHSO2-aryl, (alkyl)m-S-R17, -(alkyl)m-SO-R17, -(alkyl)m-SO2-R17, -(alkyl)m-SO2OR17, -(alkyl)mNHCOR17, -(alkyl)mCONR17R18, -(alkyl)m-CR'=NOR", -(alkyl)m-CO-R17, -(alkyl)mCO2-R17, -(alkyl)m-SO2-NR17R18, optionally substituted aryl, or optionally substituted heterocyclic; or R7 together with R6, or together with R8, forms a 5- to 7- membered ring; R8 is H, alkyl, alkoxy, hydroxyalkyl, halogen, haloalkyl, cyano, cyanoalkyl, nitro, nitroalkyl, optionally substituted aryl, optionally substituted heterocyclic, -(alkyl)m-S-R19, -(alkyl)m-SO-R19, -(alkyl)m-SO2-R19, -(alkyl)m-SO2OR19, -(alkyl)m-SO2-NR19R20, -(alkyl)mNHCOR19, -(alkyl)mCONR19R20, (alkyl)m-CR'=NOR", -(alkyl)m-CO-R19, or (alkyl)m-CO2-R19; The following proviso applies to the compounds described above: If one of R5, R6, R7, and R8 is halogen or alkyl or alkoxy, then one or more of the remainder of R5, R6, R7, and R8 is/are not halogen or alkyl, and then one or more of the remainder of R5, R6, R7, and R8 is/are not hydrogen. Also described are pharmaceutical compositions comprising the compound described above. The compounds described above are useful for the treatment of diseases and disorders that are responsive to the modulation of the AMPA receptor complex of the central nervous system.
Patent NZ-508687-A (NZ)
Title: Mechanical heart valve
Inventor: STEINSEIFER ULRICH
IPC: A61F2/24
Filed: 1999-06-02
Abstract: An improved trileaflet mechanical heart valve (100) and an improved leaflet (110) for use with such valve. The valve (100) and leaflet (110) provide improved flow characteristics, minimize blood clotting behind the leaflets, and provide more natural opening and closing times. The valve includes a valve housing (105) which contains pivot/hinge mechanism (130, 200, and 300) for allowing rotation of and retention of the leaflets (110). The valve housing (105) also includes windows or openings (125) which allows for complete washing of the pivot/hinge mechanism (130, 200, and 300) as well as the leaflets (110). The leaflets (110) are airfoil-like having a complex S-shaped curvature on their outer surface. This geometry, when combined with the location of the leaflet's pivot axis, causes a tendency for the leaflet (110) to rotate towards the closed position. Thus, the leaflet (110) begins to close much earlier than a conventional leaflet and is substantially closed before the flow reverses, similar to the function of a natural valve.
Patent NZ-510725-A (NZ)
Title: A gene with a homeodomain-like sequence encoding a protein that can induce adventitious shoot formation and branching
Inventor: KAKIMOTO TATSUO
IPC: A01H1/00
Filed: 2000-07-21
Abstract: Protein that is involved in differentiation and that has a homeodomain-like sequence. For example, there is provided a gene derived from Arabidopsis thaliana, said gene encoding a protein that has the amino acid sequence as set forth in SEQ ID NO: 2 or 4, that is involved in differentiation, and that has a homeodomain-like sequence. This gene can not only be used for the production of said protein and but for the control of plant regeneration, differentiation, growth, and the like by introducing said gene into a plant.
Patent NZ-512236-A (NZ)
Title: An infant simulator (doll) with a curved neck tube to simulate pivoting of head of baby
Inventor: JURMAIN MARY M
IPC: A63H3/36
Filed: 1998-08-25
Abstract: The infant simulator comprises a doll having at least a torso and a head pivotably connected to the torso by a neck linkage, where the neck linkage includes: i) A first collar fixedly attached to the head, ii) A second collar fixedly attached to the torso and pivotable relative to the first collar, and iii) An extension fixedly attached to one of the collars at a first end and reciprocally extending through an aperture in the other collar whereby the extension is exposed as the head pivots away from the torso.
Patent NZ-516467-A (NZ)
Title: A method of treating diseases of the central nervous system (CNS) with 2-aminoindane analogues
Inventor: CURRY KENNETH
IPC: A61P25/28
Filed: 2000-06-30
Abstract: Therapeutically active 2-aminoindane analogues of formula (I) are described. Also provided is a method of preparing compounds of formula (I), and pharmaceutical compositions comprising the compounds. The compounds act as modulators of metabotropic glutamate receptors and, as such, are useful in treating diseases of the central nervous system related to the metabotropic glutamate receptor system. Depicted is formula (I) wherein:Rl, and R2 are selected from the group comprising: 1) H; or: 2) an acidic group selected from the group comprising carboxy, phosphono, phosphino, sulfono, sulfino, borono, tetrazol,isoxazol,- (CH2) n- carboxy,- (CH2) n-phosphono,- (CH2)n-phosphino,-(CH2) n- sulfono,-(CH2) n-sulfino,-(CH2) n-borono,-(CH2) n-tetrazol, and-(CH2) n-isoxazol, where n = 1,2,3,4,5, or 6; or: X is an acidic group selected from the group comprising carboxy, phosphono, phosphino, sulfono, sulfino, borono, tetrazol, and isoxazol. Y is a basic group selected from the group comprising 1 amino,2 amino, 3 amino, quaternary ammonium salts, aliphatic 1 amino, aliphatic 2 amino, aliphatic 3 amino, aliphatic quaternary ammonium salts, aromatic 1 amino, aromatic 2 amino, aromatic 3 amino, aromatic quaternary ammonium salts, imidazol, guanidino, boronoamino, allylurea, thiourea ; m is 0 or1; R3, R4, R5, R6 are independently H, nitro, amino, halogen, tritium, trifluoromethyl, trifluoroacetyl, sulfo, carboxy, carbamoyl, sulfamoyl or acceptable esters thereof ; or a salt thereof with a pharmaceutically acceptable acid or base.
Patent NZ-517732-A (NZ)
Title: Gas storage on an adsorbent with exfoliated laminae
Inventor: MCALISTER ROY
IPC: F17C11/00
Filed: 1999-08-11
Abstract: Gases may be maintained in compact form, e.g. at energy densities comparable to that of gasoline in the case of fuel gases such as hydrogen, methane or natural gas, by storage in a relatively motion-arrested state between the exfoliated laminae of exfoliated laminar crystalline structures, e.g. exfoliated hexagonal crystalline structures such as graphite or boron nitride.
Patent NZ-521986-A (NZ)
Title: Methods and apparatus for obtaining and displaying availability information
Inventor: RHIND JULIAN D OYLY
IPC: H04N7/173
Filed: 2002-10-15
Abstract: A method of obtaining and displaying availability information to users of a reservation system is disclosed. The user enters a query specifying one or more dates and the resource for which availability is requested. The information is retrieved from a server and information on the availability of the resource on the selected dates is displayed graphically on screen in a calendar format. The query is entered into the system using a standard or modified Global Distribution System syntax.
Patent NZ-523227-A (NZ)
Title: A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
Inventor: VAN POELJE PAUL D
IPC: A61P3/04
Filed: 2001-07-05
Abstract: A pharmaceutical composition comprising a pharmaceutically effective amount of at least one insulin secretagogue (such as a sulfonylurea antidiabetic agent) and a pharmaceutically effective amount of at least one FBPase inhibitor is disclosed, wherein the composition is suitable for use in a combination therapy for treating diabetic.
Patent NZ-523633-A (NZ)
Title: Polynucleotide regulatory sequences that modify expression of endogenous and/or heterologous polynucleotides in transgenic plants
Inventor: PERERA RANJAN
IPC: C12N1/21
Filed: 2001-06-20
Abstract: Isolated plant polynucleotide regulatory sequences from eucalyptus and pine that are involved in the regulation of gene expression are disclosed, together with methods for the use of such polynucleotide regulatory regions in the modification of expression of endogenous and/or heterologous polynucleotides in transgenic plants. Particularly described are polynucleotide promoter sequences from 5'untranslated, or noncoding, regions of plant genes that initiate and regulate transcription of polynucleotides placed under their control, together with isolated polynucleotides comprising such promoter sequences.
Patent NZ-523687-A (NZ)
Title: Antimicrobial agent
Inventor: ELSSER DIETER
IPC: A23K1/16
Filed: 2001-09-27
Abstract: An antimicrobial composition comprising a cyclic compound having Formula I, wherein R1 and R2 are independently selected from -OH, =O, and -OC(O)R', wherein R' is a hydrocarbyl group; wherein R3 is selected from -OH, =O, a substitutent comprising an -OH group and -OC(O)R', wherein R' is a H or a hydrocarbyl group, wherein R4 and R5 are each independently selected from a hydrocarbyl group, H, OH, =O, and -OC(O)R', wherein R' is a H or a hydrocarbyl group or wherein R4 and R5 represent a bond with an adjacent atom on the ring of the cyclic compound; and wherein said compound comprises at least one ester group. Also disclosed a process for preventing and/or inhibiting the growth of, and/or killing, micro-organisms in a material, and the use of a cyclic compound having Formula I.
Patent NZ-523825-A (NZ)
Title: Method for producing 4-bromine-aniline derivatives
Inventor: LOCHTMAN RENE
IPC: C07C209/74
Filed: 2001-06-29
Abstract: A process for preparing 4-bromoaniline derivatives (such as 4-bromo-2-(4,5-dihydroisoxazol-3-yl)-3-methylaniline) of the formula (I) is disclosed, wherein the process comprising reacting a compound of formula (II) with a brominating agent in the presence of the solvent pyridine, wherein: R1 is C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C3-C8-cycloalkyl, halogen; R2 is C1-C6-alkyl, C1-C6-alkoxy, C3-C8-cycloalkyl, C2-C6-alkenyl, cyano or a heterocyclic radical.
Patent NZ-528803-A (NZ)
Title: A wall panel and wall structure
Inventor: MINITER FREDERICK MICHAEL
IPC: E04B2/02
Filed: 2003-10-13
Abstract: A dwelling wall comprising a structural frame of spaced apart studs and noggings disposed between an outer layer of lightweight concrete panels and an inner layer of plasterboard liner, and wherein said lightweight concrete panels are made of a concrete mix having a nominal density in the range of 500 to 1500kg/m3.
Patent NZ-528957-A (NZ)
Title: A novel coating for a sustained release pharmaceutical composition
Inventor: MULYE NIRMAL
IPC: A61K9/22
Filed: 2002-04-18
Abstract: A coating composition for coating a solid dosage form of a medicament is disclosed, where the coating composition controls the release of the medicament, said coating composition comprising (a) at least 50% (w/w) by dry weight of a water insoluble polymer insoluble in both acidic, basic and neutral pH, present in the form of an aqueous latex dispersion, (b) a water soluble non-polymeric component present in a weight ratio of about 5 to about 50% (w/w) by dry weight of the coating, having a molecular weight of less than about 15,000 daltons and water solubility in excess of 5 grams per 100 grams of water at room temperature at 1 atm pressure, said water soluble non-polymeric component being organic and either solid or liquid ; said ratio of water insoluble polymer to water soluble non-polymeric component ranges from about 95:5 to about 1:1, the solid content in the coating composition ranges from about 5% to about 25%, said water soluble component being completely dissolved in the aqueous latex dispersion. Also disclosed is a system for the controlled release of an active medicament comprising a substrate and a coating, said substrate comprising a therapeutically effective amount of a medicament in association with a pharmaceutical carrier in solid unit dosage form, said substrate being uniformly coated with the aforesaid coating composition.
Patent NZ-530843-A (NZ)
Title: Cartridge for discharging a projectile containing herbicide into plants
Inventor: HANCOCK RAYMOND HARRY
Filed: 2004-01-29
Abstract: A cartridge 1 that contains a chemical agent for treating plants and is for use in association with a projectile discharging means, such as a shotgun, is disclosed. The cartridge includes a casing 2 defining a chamber 3, at least one projectile 4 in the chamber, and a primer arranged adjacent the rear portion of the chamber to ignite a propellant charge to propel the projectile towards the front of the cartridge. The projectile contains a herbicide 5 for the treatment of plants and is discharged with sufficient force to enter a plant and release the herbicide into the plant.
Patent NZ-533933-A (NZ)
Title: Compositions and methods for the diagnosis and treatment of glioma tumor
Inventor: FRANTZ GRETCHEN
IPC: A61K47/48
Filed: 2002-12-30
Abstract: Disclosed is the use of an antibody that specifically binds to the polypeptide shown in SEQ ID No:37 for therapeutically treating a mammal having a glioma tumor comprising cells that express a protein comprising an amino acid sequence having at least 90% sequence identity to: (a) the amino acid sequence shown in SEQ ID NO:37; (b) the amino acid sequence shown in SEQ ID NO:37, lacking its associated signal peptide; or (c) an amino acid sequence encoded by a nucleic acid comprising the nucleotide sequence shown in SEQ ID NO:18. Also disclosed is a method for diagnosing glioma tumors that involves detecting the level of expression of a gene encoding a peptide comprising an amino acid sequence having at least 90% sequence identity to the sequences in (a)-(c).